Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD)
Paidas M, Triche E, James A, Ballard T, Lowry S. 347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD). American Journal Of Obstetrics And Gynecology 2013, 208: s154. DOI: 10.1016/j.ajog.2012.10.512.Peer-Reviewed Original Research